Session

Prostate cancer diagnosis

Poster Session 62

  • Location:
    Room 14c (ICM, Level 1)
  • Chairs:
     N. Al-Hamdani, Baghdad (IQ)
     F.M.J. Debruyne, Arnhem (NL)
     V. Scattoni, Milan (IT)
  • Aims and objectives of this session

    This session is aiming to find the best and specific way for early diagnosis and detection of prostate cancer and the best way to prevent the disease if possible.

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 776
Prostate cancer incidence and cardiovascular mortality among users of testosterone replacement therapy in the Finnish Prostate Cancer Screening Trial

By: Murtola T.1, Rytkönen J.2, Talala K.3, Taari K.4, Tammela T.2, Auvinen A.5

Institutes: 1Tampere University Hospital, Dept. of Urology, Tampere, Finland, 2University of Tampere, School of Medicine, Tampere, Finland, 3Finnish Cancer Registry, Dept. of Statistics, Helsinki, Finland, 4University of Helsinki, Medical School, Helsinki, Finland, 5University of Tampere, School of Health Sciences, Tampere, Finland

* 777
The impact of age-adjusted Charlson comorbidity index and age-adjusted prostate cancer specific comorbidity index in men underwent radical prostatectomy: A competing risk analysis of long-term survival data

By: Kang D.H.1, Lee J.Y.1, Jang W.S.1, Kang H.W.2, Kwon J.K.1, Rha K.H.1, Cho N.H.3, Oh C.K.4, Choi Y.D.1, Hong S.J.1, Cho K.S.1

Institutes: 1Yonsei University College of Medicine, Dept. of Urology, Urological Science Institute, Seoul, South Korea, 2Chungbuk National University College of Medicine, Dept. of Urology, Cheongju, South Korea, 3Yonsei University College of Medicine, Dept. of Pathology, Seoul, South Korea, 4Inje University College of Medicine, Dept. of Urology, Busan, South Korea

778
Increase prostate cancer detection rate from 12- to 18-core prostate biopsy in patients with serum prostate-specific antigen level of 4.0-20.0 ng/ml

By: Wang B-R.1, Chen C.C.2, Ou Y-C.2

Institutes: 1Taichung Arm Force General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan, 2Taichung Veterans General Hospital, Dept. of Urology and Dept. of Surgery, Taichung City, Taiwan

779
Comparison of MRI/ultrasound-fusion-biopsy to systematic prostate biopsy in prediction of final histopathology in prostatectomy specimen

By: Borkowetz A.1, Platzek I.2, Toma M.3, Renner T.1, Fröhner M.1, Zastrow S.1, Wirth M.1

Institutes: 1University Hospital, TU Dresden, Dept. of Urology, Dresden, Germany, 2University Hospital, TU Dresden, Dept. of Radiology, Dresden, Germany, 3University Hospital, TU Dresden, Dept. of Pathology, Dresden, Germany

780
Minimizing the Gleason score upgrade from biopsy to prostatectomy specimen through mpMRI and template mapping fusion biopsy

By: Gross O., Neuhaus L., Mortezavi A., Sulser T., Eberli D.

Institutes: University Hospital Zurich, Dept. of Urology, Zürich, Switzerland

781
Natural history of prostatic precancerous lesions: When to re-biopsy?

By: Oderda M.1, Agnello M.1, Barale M.1, Falcone M.1, Marra G.1, Preto M.1, Daniele L.2, Pacchioni D.2, Delsedime L.2, Nicolaiew N.3, Joniau S.3, De La Taille A.4, Gontero P.1

Institutes: 1University of Turin, Dept. of Surgical Sciences/Urology, Turin, Italy, 2A.O.U. Città Della Salute E Della Scienza, Dept. of Pathology, Turin, Italy, 3University Hospitals of Leuven, Dept. of Urology, Leuven, Belgium, 4C.H.U. Henri Mondor, Dept. of Urology, Creteil, France

782
Assessing the role of time from prostate cancer diagnosis to radical prostatectomy: Can surgery be postponed safely?

By: Cucchiara V., Suardi N., Gallina A., Stabile A., Picozzi M., Zaffuto E., Fossati N., Gandaglia G., Larcher A., Salonia A., Montorsi F., Briganti A.

Institutes: IRCCS Ospedale San Raffaele, Division of Oncology/Unit of Urology; URI, Milan, Italy

783
High-resolution magnetic resonance imaging differentiates between normal histomorphological signatures and prostate cancer in the resected prostate gland

By: Durand M.1, Jain M.2, Robinson B.3, Aronowitz E.4, El Douahy Y.2, Leung R.2, Sherr D.2, Ng A.4, Donzeau D.5, Amiel J.5, Pascal S.4, Villers A.6, Ballon D.4

Institutes: 1Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, INSERM U1189, Dept. of Urology, Nice, France, 2Weill Medical College of Cornell University, Dept. of Urology, New York, United States of America, 3Weill Medical College of Cornell University, Dept. of Pathology, New York, United States of America, 4Weill Medical College of Cornell University, Dept. of Radiology, New York, United States of America, 5Hôpital Pasteur 2, CHU Nice, University of Nice-Sophia-Antipolis, Dept. of Urology, Nice, France, 6CHU Lille, Université De Lille, INSERM U1189, Dept. of Urology, Lille, France

784
Impact of PI-RADS version 2 on MRI diagnosis for extracapsular extension of prostate cancer: A multireader study

By: Matsuoka Y.1, Ishioka J.1, Tanaka H.2, Inoue M.1, Ito M.1, Yoshida S.1, Yokoyama M.1, Numao N.1, Saito K.1, Fujii Y.1, Kihara K.1

Institutes: 1Tokyo Medical and Dental University Graduate School, Dept. of Urology, Tokyo, Japan, 2Ochanomizu Surugadai Clinic, Dept. of Radiology, Tokyo, Japan

785
Limitations in elastography based prostate biopsy

By: Grindei-Nevrincean M.1, Schiffmann J.1, Tian Z.2, Yassin D-J.1, Steinwender T.1, Leyh-Bannurah S-R.2, Randazzo M.3, Kwiatkowski M.3, Karakiewicz P.I.2, Hammerer P.1, Manka L.1

Institutes: 1Academic Hospital Braunschweig, Dept. of Urology, Braunschweig, Germany, 2University of Montreal Health Center, Dept. of Cancer Prognostics and Health Outcomes, Montreal, Canada, 3Cantonal Hospital Aarau, Dept. of Urology, Aarau, Switzerland

786
Phenotypic and molecular characterization of circulating tumor cells (EGFR and AR) and its correlation with prostate biopsy in early-stage prostate cancer

By: Puche Sanz I.1, Flores-Martín J.1, Vázquez Alonso F.1, Serrano Fernández M.J.2, Cózar Olmo J.M.1

Institutes: 1Complejo Hospitalario Universitario De Granada, Dept. of Urology, Granada, Spain, 2Centro Pfizer-Universidad De Granada-Junta De Andalucía De Genómica E Investigación Oncológica (GENY, Dept. of Circulating Tumor Cells, Granada, Spain